Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus

Clin Pharmacol Ther. 1994 Sep;56(3):272-8. doi: 10.1038/clpt.1994.137.


Zidovudine is metabolized to an inactive 5'-glucuronide and has a short plasma half-life requiring frequent dosing. The present study in six patients without symptoms who were infected with human immunodeficiency virus was undertaken to determine if coadministration of valproic acid which, like zidovudine, is metabolized by glucuronidation, would alter zidovudine disposition. Under steady-state conditions for both drugs, the plasma area under the curve for zidovudine increased twofold with a corresponding decline in its oral clearance when given with valproic acid. The mean 5'-glucuronide/zidovudine urinary excretion ratio was reduced by more than 50%, and the amount of unconjugated zidovudine recovered in urine increased by more than twofold. There was no significant increase in the plasma half-life of zidovudine. The effects of valproic acid on zidovudine glucuronidation were related to plasma valproic acid concentrations. Valproic acid inhibits glucuronidation of zidovudine and increases its oral bioavailability.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Biological Availability
  • Drug Synergism
  • HIV Infections / blood*
  • HIV Infections / drug therapy
  • Half-Life
  • Humans
  • Linear Models
  • Male
  • Middle Aged
  • Valproic Acid / blood
  • Valproic Acid / pharmacology*
  • Zidovudine / analogs & derivatives
  • Zidovudine / blood
  • Zidovudine / pharmacokinetics*
  • Zidovudine / therapeutic use


  • Zidovudine
  • Valproic Acid
  • 3'-azido-3'-deoxy-5'-O-beta-glucopyranuronosylthymidine